Functional analysis of the two cytidine deaminase domains in APOBEC3G

Virology

Volumn 414, Issue 2, 2011, Pages 130-136

  Li, Xiaoyu ^a   Ma, Jing ^a,d,e   Zhang, Quan ^a   Zhou, Jinming ^a   Yin, Xiao ^a   Zhai, Congjie ^a   You, Xuefu ^a   Yu, Liyan ^a   Guo, Fei ^b   Zhao, Lixun ^a   Li, Zelin ^c   Zeng, Yi ^c   Cen, Shan ^a,d,e  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b INSTITUTE OF PATHOGEN BIOLOGY   (China)

^c BEIJING UNIVERSITY OF TECHNOLOGY   (China)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Antiviral; APOBEC3G; Cytidine deaminase; Degradation; Encapsidation; HIV 1; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; COMPLEMENTARY DNA; CYTIDINE DEAMINASE; MUTANT PROTEIN; VIF PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DEAMINATION; EMBRYO; ENZYME ACTIVITY; GENE MUTATION; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; VIRION; VIRUS CAPSID;

AMINO ACID SEQUENCE; CELL LINE; CYTIDINE DEAMINASE; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; SEQUENCE ALIGNMENT; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79955912281     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.03.014     Document Type: Article

References (60)

1. Accola M.A., Strack B., Gottlinger H.G. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J. Virol. 2000, 74:5395-5402.
2. Bishop K.N., Verma M., Kim E.Y., Wolinsky S.M., Malim M.H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 2008, 4:e1000231.
3. Cen S., Guo F., Niu M., Saadatmand J., Deflassieux J., Kleiman L. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 2004, 279:33177-33184.
4. Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., Landau N.R., Weitzman M.D. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 2006, 16:480-485.
5. Chen K.M., Harjes E., Gross P.J., Fahmy A., Lu Y., Shindo K., Harris R.S., Matsuo H. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 2008, 452:116-119.
6. Conticello S.G., Harris R.S., Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 2003, 13:2009-2013.
7. Conticello S.G., Thomas C.J., Petersen-Mahrt S.K., Neuberger M.S. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 2005, 22:367-377.
8. Cullen B.R. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 2006, 80:1067-1076.
9. Dang Y., Siew L.M., Wang X., Han Y., Lampen R., Zheng Y.H. Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 2008, 283:11606-11614.
10. Dettenhofer M., Cen S., Carlson B.A., Kleiman L., Yu X.F. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J. Virol. 2000, 74:8938-8945.
11. Fisher A.G., Ensoli B., Ivanoff L., Chamberlain M., Petteway S., Ratner L., Gallo R.C., Wong-Staal F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 1987, 237:888-893.
12. Friew Y.N., Boyko V., Hu W.S., Pathak V.K. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology 2009, 6:56.
13. Gabuzda D.H., Lawrence K., Langhoff E., Terwilliger E., Dorfman T., Haseltine W.A., Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 1992, 66:6489-6495.
14. Gibbs J.S., Regier D.A., Desrosiers R.C. Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res. Hum. Retroviruses 1994, 10:607-616.
15. Guo F., Cen S., Niu M., Saadatmand J., Kleiman L. Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 2006, 80:11710-11722.
16. Hache G., Liddament M.T., Harris R.S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 2005.
17. Harari A., Ooms M., Mulder L.C., Simon V. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 2009, 83:295-303.
18. Harris R.S., Liddament M.T. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 2004, 4:868-877.
19. Huang Y., Kong W.P., Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 2001, 75:4947-4951.
20. Huthoff H., Autore F., Gallois-Montbrun S., Fraternali F., Malim M.H. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 2009, 5:e1000330.
21. Iwatani Y., Takeuchi H., Strebel K., Levin J.G. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 2006, 80:5992-6002.
22. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79:285-296.
23. Kan N.C., Franchini G., Wong S.F., DuBois G.C., Robey W.G., Lautenberger J.A., Papas T.S. Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera. Science 1986, 231:1553-1555.
24. Kao S., Khan M.A., Miyagi E., Plishka R., Buckler-White A., Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 2003, 77:11398-11407.
25. Khan M.A., Goila-Gaur R., Kao S., Miyagi E., Walker R.C., Strebel K. Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization. Retrovirology 2009, 6:99.
26. Khorchid A., Halwani R., Wainberg M.A., Kleiman L. Role of RNA in facilitating Gag/Gag-Pol interaction. J. Virol. 2002, 76:4131-4137.
27. Kohli R.M., Abrams S.R., Gajula K.S., Maul R.W., Gearhart P.J., Stivers J.T. A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J. Biol. Chem. 2009, 284:22898-22904.
28. LaRue R.S., Jonsson S.R., Silverstein K.A., Lajoie M., Bertrand D., El-Mabrouk N., Hotzel I., Andresdottir V., Smith T.P., Harris R.S. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol. Biol. 2008, 9:104.
29. Lee T.H., Coligan J.E., Allan J.S., McLane M.F., Groopman J.E., Essex M. A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science 1986, 231:1546-1549.
30. Li X.Y., Guo F., Zhang L., Kleiman L., Cen S. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 2007, 282:32065-32074.
31. Luo K., Liu B., Xiao Z., Yu Y., Yu X., Gorelick R., Yu X.F. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 2004, 78:11841-11852.
32. Luo K., Wang T., Liu B., Tian C., Xiao Z., Kappes J., Yu X.F. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 2007, 81:7238-7248.
33. Madani N., Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 1998, 72:10251-10255.
34. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114:21-31.
35. Marin M., Rose K.M., Kozak S.L., Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 2003, 9:1398-1403.
36. Navarro F., Bollman B., Chen H., Konig R., Yu Q., Chiles K., Landau N.R. Complementary function of the two catalytic domains of APOBEC3G. Virology 2005, 333:374-386.
37. Newman E.N., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 2005, 15:166-170.
38. Nguyen K.L., Llano M., Akari H., Miyagi E., Poeschla E.M., Strebel K., Bour S. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 2004, 319:163-175.
39. OhAinle M., Kerns J.A., Malik H.S., Emerman M. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 2006, 80:3853-3862.
40. Rausch J.W., Chelico L., Goodman M.F., Le Grice S.F. Dissecting APOBEC3G substrate specificity by nucleoside analog interference. J. Biol. Chem. 2009, 284:7047-7058.
41. Rogozin I.B., Basu M.K., Jordan I.K., Pavlov Y.I., Koonin E.V. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 2005, 4:1281-1285.
42. Sawyer S.L., Emerman M., Malik H.S. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2004, 2:E275.
43. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
44. Simon J.H., Gaddis N.C., Fouchier R.A., Malim M.H. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 1998, 4:1397-1400.
45. Simon J.H., Malim M.H. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J. Virol. 1996, 70:5297-5305.
46. Sodroski J., Goh W.C., Rosen C., Tartar A., Portetelle D., Burny A., Haseltine W. Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science 1986, 231:1549-1553.
47. Stopak K., de Noronha C., Yonemoto W., Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 2003, 12:591-601.
48. Strebel K., Daugherty D., Clouse K., Cohen D., Folks T., Martin M.A. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 1987, 328:728-730.
49. Svarovskaia E.S., Xu H., Mbisa J.L., Barr R., Gorelick R.J., Ono A., Freed E.O., Hu W.S., Pathak V.K. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 2004, 279:35822-35828.
50. Wang T., Tian C., Zhang W., Luo K., Sarkis P.T., Yu L., Liu B., Yu Y., Yu X.F. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol. 2007, 81:13112-13124.
51. Wang T., Tian C., Zhang W., Sarkis P.T., Yu X.F. Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. J. Mol. Biol. 2008, 375:1098-1112.
52. Wedekind J.E., Dance G.S., Sowden M.P., Smith H.C. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 2003, 19:207-216.
53. Yu Q., Chen D., Konig R., Mariani R., Unutmaz D., Landau N.R. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 2004, 279:53379-53386.
54. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060.
55. Zennou V., Perez-Caballero D., Gottlinger H., Bieniasz P.D. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 2004, 78:12058-12061.
56. Zhang J., Webb D.M. Rapid evolution of primate antiviral enzyme APOBEC3G. Hum. Mol. Genet. 2004, 13:1785-1791.
57. Zhang K.L., Mangeat B., Ortiz M., Zoete V., Trono D., Telenti A., Michielin O. Model structure of human APOBEC3G. PLoS ONE 2007, 2:e378.
58. Zhang L., Saadatmand J., Li X., Guo F., Niu M., Jiang J., Kleiman L., Cen S. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology 2008, 370:113-121.
59. Zhang W., Du J., Yu K., Wang T., Yong X., Yu X.F. Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions. J. Virol. 2010, 84:12903-12913.
60. Zhen A., Wang T., Zhao K., Xiong Y., Yu X.F. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J. Virol. 2010, 84:1902-1911.